Chapter 1: Traditional Medical System for Sustainable Healthcare in India
Pulok K Mukherjee, Subhadip Banerjee, C K Katiyar, Shivani Sharma, Naibedya Chattopadhyay
Chapter 2: Modern Drug Discovery and Development for TB- The India narrative.
Tanjore S BalganeshJagadeesh J Bhat and Bheemarao Ugarkar
Chapter 3: Indian Discovery Effort in the Quest of Novel Antibiotics.
Mahesh V Patel, Sachin S Bhagwat and Prasad K Deshpande,
Chapter 4: New Drug Discovery and Development in India to Counter Malaria,
Niti Kumar and Saman Habib
Chapter 5: Modern Drug Discovery and Development in the area of Leishmaniasis
Neena Goyal, Manveer Pateland Sanjay Batra
Chapter 6: Modern Drug Discovery and Development: Diabetes and lifestyle disorders
Part I - Introduction to Diabetes and Prevalence in India
Parimal Misra and Ranjan Chakrabarti
Part II - Type 2 Diabetes Mellitus: Marketed drugs and mechanisms
Parimal Misra and Ranjan Chakrabarti
Part III - Anti-diabetes research in India: Contributions from industrial organizations
Sarbani Pal, and Manojit Pal
Part IV - Indian Academia Tryst with Cardio-metabolic Drug Discovery and Development
Manoj K Barthwal
Chapter 7: Modern drug discovery and development in the area of Cancer: Indian context
Tapas K Kundu, Anand P Kulkarni, Dipak Datta, Sweta Sikder
Chapter 8: Biopharmaceutical development in India: recommendations on collaboration and innovation to enable affordable healthcare. Narendra Chirmule, Shilpa Bhat, Sabyasachi Mondal,
Chapter 9: Regulatory requirements and Quality Standards in Clinical Trials Journey
B George, SK Kulkarni and NA Kshirsagar
Chapter 10: New Drug Discovery and Development - Indian Pharmaceutical Industry
Dr Madhu Dikshit, a highly respected researcher and former Director of the CSIR-Central Drug Research Institute, Lucknow, India, has made significant contributions to the general area of Molecular Pharmacology with a special interest in redox biology. Dr Dikshit’s research has impacted the area of neutrophil biology by enhancing our understanding of e.g. chemotaxis, phagocytosis, apoptosis and also differentiation. Her pioneering work has helped identify the molecular mechanisms involved in the translocation of Nitric Oxide Synthase to the phagosomal compartment and the inflammatory potential of neutrophil extracellular traps. At the CSIR-CDRI, she initiated and led the successful anti-thrombotic drug discovery program, in the context of which two new chemical entities advanced to the pre-clinical stage and one has recently received approval for Phase I clinical trials. Dr Dikshit has published more than 170 papers in peer-reviewed journals, holds eight patents and has supervised more than 30 PhD students. Presently she is the National Chair at Translational Health Sciences & Technology Institute (THSTI), Faridabad and heads its Non-Communicable Disease Program.
Over the years, India has attained a prominent global position in the manufacture of Generic Drugs. This success can be attributed to its synthetic organic chemistry and chemical engineering strengths, nurtured by the timely policies of the Government of India. However, breakthrough successes in New Drug Discovery have remained elusive, despite the brilliant and sustained efforts of many Indian researchers and Pharma establishments. The Indian National Science Academy thought it appropriate to document India’s New Drug Discovery Research (NDDR) journey to date. Gathering contributions from prominent researchers in the Indian Pharma Industry and Academia, this book highlights their efforts, achievements, and the status quo of Indian NDDR.